[68Ga]Ga-mDesmo PET-CT 分子影像新技术用于定位库欣病肿瘤
本研究将经修饰的去氨加压素(mDesmo)用68Ga标记,对30例库欣综合征患者行[68Ga]Ga-mDesmo PET成像,并与增强MRI比较,以病理为金标准;在24例初治库欣病患者中,[68Ga]Ga-mDesmo全部识别出促肾上腺皮质激素瘤(100%),而增强MRI仅识别16例(67%)。
要点
- [68Ga]Ga-mDesmo在24例初治库欣病患者中全部识别促肾上腺皮质激素瘤,微腺瘤诊断准确率100%。
- 增强MRI在24例中识别16例病灶(67%),微腺瘤诊断准确率53%。
- 异位库欣综合征患者垂体未见[68Ga]Ga-mDesmo摄取。
核心结论
- 本研究显示[68Ga]Ga-mDesmo成像是一种有效的在体分子影像技术,可勾画促肾上腺皮质激素瘤,不论腺瘤大小,其准确性超过增强MRI和BIPSS。
研究设计与样本
- 研究将V1b受体激动剂去氨加压素的修饰形式mDesmo与68Ga螯合,制备新型PET显像药物。
- 共筛查234例库欣综合征患者,其中30例接受[68Ga]Ga-mDesmo成像。
- 记录患者人口学与激素水平(血浆皮质醇和ACTH),以促肾上腺皮质激素瘤的组织病理学证据为参考标准,比较增强MRI与[68Ga]Ga-mDesmo的诊断准确性。
主要发现
- 队列包括男性10例(33%,CI:16-50%)和女性20例(67%,CI:50-84),平均年龄33.5±13.5岁。
- 30例库欣综合征患者中,24例为初治库欣病,其中17例(71%,CI:53-89%)为微腺瘤,7例(30%,CI:12-48%)为大腺瘤;4例(13%,CI:0-25%)为异位库欣综合征。
- 增强MRI在24例中识别16例病灶(67%,CI:48-86%),[68Ga]Ga-mDesmo在全部24例中识别出促肾上腺皮质激素瘤(100%,CI:86-100%)。
- 微腺瘤患者中,增强MRI诊断准确率为53%(CI:29-77%),[68Ga]Ga-mDesmo为100%(CI:86-100%)。
- 异位库欣综合征患者垂体未见[68Ga]Ga-mDesmo摄取。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Localizing the source of adrenocorticotropic hormone (ACTH) in patients with ACTH-dependent Cushing's syndrome (CS) poses significant challenges. There is a pressing need for novel imaging modalities that provide both anatomical delineation and functional confirmation of corticotropinomas. METHODS: This study utilized a modified form of desmopressin (mDesmo), an agonist of the V1b receptor, which is overexpressed in tumoral corticotrophs. After modification, radionuclide 68Ga was chelated to produce a new radiopharmaceutical for positron emission tomography (PET) imaging. A total of 234 patients with CS were screened and 30 underwent [68Ga]Ga-mDesmo imaging. Patient demographics and hormonal levels (plasma cortisol and ACTH) were recorded, and the diagnostic accuracy of contrast-enhanced MRI (CE-MRI) and [68Ga]Ga-mDesmo was compared, with histopathological evidence of a corticotropinoma serving as the reference standard. RESULTS: The cohort comprised 10 males (33%, CI: 16-50%) and 20 females (67%, CI: 50-84), with a mean age of 33.5 ± 13.5 years. Of 30 patients with CS, 24 patients had treatment naïve Cushing's disease (CD) of which 17 (71%, CI: 53-89%) had microadenomas and 7 (30%, CI: 12-48%) had macroadenoma; 4 (13%, CI: 0-25%) patients had ectopic Cushing syndrome (ECS). CE-MRI identified lesions in 16 patients (67%, CI: 48-86%), while [68Ga]Ga-mDesmo successfully identified corticotropinomas in all 24 patients (100%, CI: 86-100%). In patients with microadenomas, CE-MRI had a diagnostic accuracy of 53% (CI: 29-77%), whereas [68Ga]Ga-mDesmo achieved 100% (CI: 86-100%). There was no uptake of [68Ga]Ga-mDesmo in the pituitary of patients with ECS. CONCLUSION: This study demonstrates that [68Ga]Ga-mDesmo imaging is an effective in vivo molecular imaging technique for delineating corticotropinomas, surpassing the accuracy of CE-MRI and BIPSS, regardless of adenoma size. TRIAL REGISTRATION NUMBER: CTRI/2022/08/044615 dated 03/08/2022.
引用
- Walia R, Chakraborty AM, Pandey S, et al. A novel molecular imaging technique using [68Ga]Ga-mDesmo PET-CT for localizing tumors in Cushing's disease. Eur J Nucl Med Mol Imaging. 2025. PMID: 40304780. doi:10.1007/s00259-025-07304-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。